Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To characterise the relative safety profile of tofacitinib to biologic disease-modifying antirheumatic drugs (bDMARDs), the accrued patient-years (pt-yrs) of exposure needed in an RA clinical trial programm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Rheumatol
Main Authors: Curtis, Jeffrey R., Zhang, Richard, Krishnaswami, Sriram, Anisfeld, Andrew, Chen, Yan, Strengholt, Sander, Chen, Connie, Geier, Jamie
Formato: Artigo
Idioma:Inglês
Publicado em: Springer London 2016
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5323490/
https://ncbi.nlm.nih.gov/pubmed/27470086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10067-016-3359-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados